Irving-based McKesson Corp. has agreed to acquire a controlling interest in Community Oncology Revitalization Enterprise Ventures LLC (Core Ventures) for about $2.49 billion in cash, representing a 70% ownership.

Core Ventures is a business and administrative services organization that was established by Florida Cancer Specialists & Research Institute LLC (FCS), a physician-owned community oncology practice. FCS physicians will continue to retain a minority interest in Core Ventures, McKesson said.

“This milestone marks an important step forward in our efforts to advance community-based oncology care,” McKesson CEO Brian Tyler said in a statement. “By growing our Oncology platform, we’ll bring advanced treatments and improved care experiences to patients, while also reducing the overall cost of care. FCS and Core Ventures’ expertise and patient-first approach align with our commitment to accelerating clinical development, improving patient outcomes, and expanding access to quality cancer care in the community.”

“We’re also pleased to welcome Florida Cancer Specialists & Research Institute to The US Oncology Network,” he added, “reinforcing our dedication to empowering community-based providers to independently thrive in today’s rapidly evolving healthcare landscape.”

Following completion of the transaction, Core Ventures will be part of the Oncology platform, and financial results will be reported within McKesson’s U.S. Pharmaceutical segment. After the close, FCS—a practice with more than 250 physicians and 280 advanced practice providers across nearly 100 locations in Florida—will remain independently owned and FCS will join McKesson’s The US Oncology Network, a leading oncology organization, dedicated to advancing local and affordable cancer care and better patient outcomes.

‘Exceptional care to cancer patients’ for over 40 years

McKesson—which became North Texas’ top-earning corporation in 2023 with the departure of Exxon Mobil’s HQ to Houston—said the FCS has provided exceptional care to cancer patients for over 40 years.

During that time, services have grown to include clinical trials, diagnostic imaging, medical oncology and chemotherapy infusion, integrative therapy, molecular and pathology lab services, radiation oncology, next-generation sequencing, medically integrated dispensing, and data services, McKesson said. FCS currently conducts clinical trials through the Sarah Cannon Research Institute, one of the world’s leading oncology research organizations conducting community-based clinical trials.

By joining The Network, FCS will have access to McKesson’s differentiated Oncology platform, including best-in-class oncology care products and services.

“Above all else, our patients are the true beneficiaries of this transaction, as we seek to drive meaningful outcomes and deliver sustained value with every interaction. Through the power of our combined operational expertise, we can bolster community oncology’s role in increasing access to high-quality, affordable care,” Lucio N. Gordan, MD, president and managing physician of FCS, said in a statement.

“This is a historic moment for FCS and reflects the evolution of our practice and the forward-thinking of physician leadership, our board, and the entire organization at large,” FCS CEO Nathan H. Walcker added. “The US Oncology Network and FCS share a mission and we both aim to strengthen patient-centered cancer care in the community to improve outcomes. We are thrilled to partner with McKesson and join The Network, which furthers the joint commitment to bringing the best medicine and innovation for patients into communities across Florida.”

McKesson Corp. is a diversified healthcare services leader dedicated to advancing health outcomes for patients everywhere. Its teams partner with biopharma companies, care providers, pharmacies, manufacturers, governments, and others to deliver insights, products, and services to help make quality care more accessible and affordable.

Get on the list.
Dallas Innovates, every day.

Sign up to keep your eye on what’s new and next in Dallas-Fort Worth, every day.